UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic

Gut, 2009-07, Vol.58 (7), p.904-909

2009

Link zum Volltext

Verfügbarkeit prüfen

Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

Journal of Crohn's and colitis, 2019-09, Vol.13 (9), p.1111-1120

2019

Link zum Volltext

Verfügbarkeit prüfen

High-resolution esophageal manometry: addressing thermal drift of the manoscan system

Neurogastroenterology and motility, 2012-01, Vol.24 (1), p.61-e11

2012

Link zum Volltext

Verfügbarkeit prüfen

Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations?

Frontline gastroenterology, 2015-07, Vol.6 (3), p.156-160

2015

Link zum Volltext

Verfügbarkeit prüfen

The development of squamo-columnar junction locator probe and its performance on bench studies

Gut, 2011-04, Vol.60 (Suppl 1), p.A182-A182

2011

Link zum Volltext

Verfügbarkeit prüfen

Squamo-columnar junction locator probe: an in vivo validation study

Gut, 2011-04, Vol.60 (Suppl 1), p.A181-A182

2011

Link zum Volltext

Verfügbarkeit prüfen

High resolution oesophageal manometry: addressing thermal drift

Gut, 2011-04, Vol.60 (Suppl 1), p.A22-A23

2011

Link zum Volltext

Verfügbarkeit prüfen

P1055 Intravenous to subcutaneous infliximab switch may reduce the risk of immunogenicity related treatment failure and can be used to facilitate immunomodulator withdrawal

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1900-i1900

2024

Link zum Volltext

Verfügbarkeit prüfen

P327 Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i347-i348

2022

Link zum Volltext

Verfügbarkeit prüfen

P504 Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i465-i466

2022

Link zum Volltext

Verfügbarkeit prüfen

P700 Perceptions towards established and emerging dietary therapies for Crohn’s disease management among the adult patients: results from a questionnaire survey

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i833-i833

2023

Link zum Volltext

Verfügbarkeit prüfen

P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i474-i474

2022

Link zum Volltext

Verfügbarkeit prüfen

P705 Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i837-i837

2023

Link zum Volltext

Verfügbarkeit prüfen

P408 Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i399-i400

2022

Link zum Volltext

Verfügbarkeit prüfen

P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i560-i560

2023

Link zum Volltext

Verfügbarkeit prüfen

P804 Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance (GENIE)

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i937-i938

2023

Link zum Volltext

Verfügbarkeit prüfen

P328 Holistic well-being as Patient-reported outcomes (PROs) in translational IBD research: Prospective capture of CUCQ32 as study endpoints for mechanistic biomarker MUSIC/GIDAMPs study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i467-i467

2023

Link zum Volltext

Verfügbarkeit prüfen

P518 Dietary and non-dietary predictors of treatment response to adalimumab in anti-TNFα-naïve adults with Crohn’s disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1023-i1023

2024

Link zum Volltext

Verfügbarkeit prüfen

P681 Preliminary data from the Biologic and Partial Enteral Nutrition in Crohn’s Disease Study (BIOPIC)

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1294-i1295

2024

Link zum Volltext

Verfügbarkeit prüfen

P875 Filgotinib in ulcerative colitis: early real-world multicentre UK experience

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1616-i1617

2024

Link zum Volltext

Verfügbarkeit prüfen

P483 Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S424-S426

2020

Link zum Volltext

Verfügbarkeit prüfen

P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S488-S488

2020

Link zum Volltext

Verfügbarkeit prüfen

P644 Post-operative Crohn’s disease recurrence in Glasgow: How common is it and does deprivation matter?

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S533-S533

2020

Link zum Volltext

Verfügbarkeit prüfen

P456 Longer-term outcomes in acute severe colitis

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S407-S407

2020

Link zum Volltext

Verfügbarkeit prüfen

An unusual infection in an injecting drug user

Scottish medical journal, 2011-02, Vol.56 (1), p.59

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Paradox of gastric cardia: it becomes more acidic following meals while the rest of stomach becomes less acidic

Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

High-resolution esophageal manometry: addressing thermal drift of the manoscan system

Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations?

The development of squamo-columnar junction locator probe and its performance on bench studies

Squamo-columnar junction locator probe: an in vivo validation study

High resolution oesophageal manometry: addressing thermal drift

P1055 Intravenous to subcutaneous infliximab switch may reduce the risk of immunogenicity related treatment failure and can be used to facilitate immunomodulator withdrawal

P327 Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring

P504 Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease

P700 Perceptions towards established and emerging dietary therapies for Crohn’s disease management among the adult patients: results from a questionnaire survey

P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review

P705 Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes

P408 Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis

P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease

P804 Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance (GENIE)

P328 Holistic well-being as Patient-reported outcomes (PROs) in translational IBD research: Prospective capture of CUCQ32 as study endpoints for mechanistic biomarker MUSIC/GIDAMPs study

P518 Dietary and non-dietary predictors of treatment response to adalimumab in anti-TNFα-naïve adults with Crohn’s disease

P681 Preliminary data from the Biologic and Partial Enteral Nutrition in Crohn’s Disease Study (BIOPIC)

P875 Filgotinib in ulcerative colitis: early real-world multicentre UK experience

P483 Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease

P582 Adalimumab therapeutic drug monitoring: Does time of testing matter?

P644 Post-operative Crohn’s disease recurrence in Glasgow: How common is it and does deprivation matter?

P456 Longer-term outcomes in acute severe colitis

An unusual infection in an injecting drug user

Suchergebnisse filtern